Alexion Pharmaceuticals, Inc.
352 Knotter Drive, P.O. Box 868
Cheshire, CT 06410
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of therapeutic products to treat patients with a wide array of severe disease states, including hematologic, cardiovascular and autoimmune disorders. The company's pipeline of antibody therapeutics is specifically focused on providing important treatment advances in areas of severe unmet medical need. Alexion is in the last phase of clinical development for its two lead product candidates and is initiating preparations for commercialization. The first lead product candidate, eculizumab, targets the treatment of a rare and severe hematologic disorder known as PNH. The second product candidate, pexelizumab, which is being developed in collaboration with Procter & Gamble Pharmaceuticals, is aimed at treating patients undergoing open heart surgery as well as patients suffering from an acute heart attack. The company was founded in New Haven, Connecticut in 1992.
C5 inhibitors, rare blood disorders, cardiovascular disease, and autoimmune disease.
Stock Symbol: ALXN
CT Employees: 175
World Employees: 200